Does accounting for seizure frequency variability increase clinical trial power? - Wikidata - awgldk - TriplyDB

Does accounting for seizure frequency variability increase clinical trial power?

Does accounting for seizure frequency variability increase clinical trial power?

http://www.wikidata.org/entity/Q50509778

about

Is seizure frequency variance a predictable quantity?Common data elements for epilepsy mobile health systems.

P2860

Q50104990-88FD41A2-32F1-4216-8FDE-5D4EF59742D5 Q52617159-E972038B-C791-48B7-9FCD-E53306D5F3AA

P2860

Does accounting for seizure frequency variability increase clinical trial power?

http://www.wikidata.org/entity/Q50509778

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Does accounting for seizure frequency variability increase clinical trial power?

@en

Does accounting for seizure frequency variability increase clinical trial power?

@nl

type

label

Does accounting for seizure frequency variability increase clinical trial power?

@en

Does accounting for seizure frequency variability increase clinical trial power?

@nl

prefLabel

Does accounting for seizure frequency variability increase clinical trial power?

@en

Does accounting for seizure frequency variability increase clinical trial power?

@nl

P1433

Q50509778-2DBE06D0-8D9F-4D58-9148-3FC6453102BF

P1476

Q50509778-71F902FB-A25A-49DD-A58A-BCC3386F8BC6

P2093

Q50509778-09075263-0DEC-4291-BE5B-05712789307F

Q50509778-20D8B30F-8FF4-41CF-BA7C-E52E6A53569C

Q50509778-30347FE2-7BDF-49C4-AE0F-4C2C5F9BF801

Q50509778-8EDC583F-FD43-4DDB-9013-5CCE2BF3DE6F

Q50509778-9AD2EEBA-8EA3-41DC-8E04-B7315B5C654F

Q50509778-A4AC93AE-D674-4E7D-B9C1-86ED8B0C0D47

Q50509778-B3BF4EA1-ED96-444A-A11C-02213D0F9D50

Q50509778-C0D132C5-254F-4B25-A54B-C3689BABB305

Q50509778-C6394583-11A9-4405-AB3D-C9B476B05ECD

Q50509778-F1DD44FF-CD13-4AB6-BDC2-47571432E230

P2860

Q50509778-06881EDF-141A-4B31-B153-8B3D1979DD19

Q50509778-086879CE-A892-4202-9446-54ED010D5815

Q50509778-0E0A11AF-B8A0-437B-B6CE-DA790139489E

Q50509778-0EB3044E-E4BC-4C2E-AD37-93AFBB076D34

Q50509778-2B8F9B54-C63F-483C-A19F-BEDABF1B941C

Q50509778-2F7FB6E6-12F9-425A-872C-DA25380C8A73

Q50509778-3064B3DA-ABD4-4A03-BE0C-7E7D16B7D850

Q50509778-40C1A643-1009-48DE-B4E5-866C7BC23CB1

Q50509778-573791A4-5BD2-450A-AE28-28A804F707E5

Q50509778-5C736D5C-FCF7-4282-B952-58A92202375C

P304

Q50509778-8E2FF07B-B6DF-460B-9666-A5E90732C1A6

P31

Q50509778-BB9340C5-71F2-4331-B8DB-6477C5F98AFB

P356

Q50509778-1203B8A6-3424-448B-B08E-B6CDA8BCDF04

P478

Q50509778-CC90ECF0-3D24-4A58-871F-1B2627E5ACB1

P50

Q50509778-0DE72484-A025-42B0-AE56-3FFDCAC6328F

Q50509778-1ADED4F6-9141-49FC-89B7-8A26FBAB48BB

Q50509778-3D206AFE-93E3-4409-A2DC-BF48DE7594E4

Q50509778-B23AA13D-14BC-4F28-8575-388E2F8F1697

P577

Q50509778-77E1977E-4630-4699-ADB1-DED6975071A3

P698

Q50509778-FB3B7162-37BE-43ED-B574-262849E0CEB8

P932

Q50509778-12ECB50E-FCED-4E60-97A8-DDEB15089E66

P356

J.EPLEPSYRES.2017.07.013

P1433

Epilepsy Research

P1476

Does accounting for seizure frequency variability increase clinical trial power?

@en

P2093

Alex Strashny

http://www.w3.org/2001/XMLSchema#string

Carl Pieper

http://www.w3.org/2001/XMLSchema#string

Daniel Lowenstein

http://www.w3.org/2001/XMLSchema#string

Daniel M Goldenholz

http://www.w3.org/2001/XMLSchema#string

John Hixson

http://www.w3.org/2001/XMLSchema#string

Kamil Detyniecki

http://www.w3.org/2001/XMLSchema#string

Robert Moss

http://www.w3.org/2001/XMLSchema#string

Sabrina Cristofaro

http://www.w3.org/2001/XMLSchema#string

Sheryl Haut

http://www.w3.org/2001/XMLSchema#string

Shira R Goldenholz

http://www.w3.org/2001/XMLSchema#string

P2860

Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304

Adaptive Designs for Clinical Trials

Early identification of refractory epilepsy

Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials

Confusing placebo effect with natural history in epilepsy: A big data approach

Modeling longitudinal daily seizure frequency data from pregabalin add-on treatment.

The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach.

Response to placebo in clinical epilepsy trials--Old ideas and new insights

Patterns of treatment response in newly diagnosed epilepsy.

Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial.

P304

145-151

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EPLEPSYRES.2017.07.013

http://www.w3.org/2001/XMLSchema#string

P478

137

http://www.w3.org/2001/XMLSchema#string

P50

Jacqueline French

Ruben Kuzniecky

Philippa J Karoly

P577

2017-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28781216

http://www.w3.org/2001/XMLSchema#string

P932

5650933

http://www.w3.org/2001/XMLSchema#string